The Acute Effect of Atorvastain on Renal Function in Patients With Type II Diabetes

The Acute Effect of Atorvastatin on Renal Sodium Excretion, Glomerular Filtration Rate, Tubular Function and Vasoactive Hormones in Patients With Non-Insulin Dependent Type II Diabetes.

Status

Completed

Phases

Phase 4

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00678522

Enrollment

Registered

2008-05-15

Start date

2007-09-30

Completion date

2008-05-31

Last updated

2008-05-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Healthy Subjects

Keywords

Atorvastatin, Renal function, Hemodynamics, Diabetes type II, sodium excretion

Brief summary

We wanted to test the hypothesis that acute treatment with atorvastatin changes renal sodium excretion, glomerular filtration rate, tubular function and vasoactive hormones in patients with type II diabetes, not in treatment with insulin.

Interventions

DRUGAtorvastatin

80 mg atorvastatin daily on two following days

Study design

Allocation

RANDOMIZED

Intervention model

CROSSOVER

Primary purpose

TREATMENT

Masking

DOUBLE (Subject, Investigator)

Eligibility

Sex/Gender

ALL

Age

40 Years to 70 Years

Healthy volunteers

Inclusion criteria

1. Age: 40-70 yrs 2. estimated GFR between 30 and 90 ml/min 3. BMI\<35 4. Fertile women had to use oral contraceptives or IUD 5. HbA1c\< 10% 6. Urine-albumin\<1,5 g/l

Exclusion criteria

1. Treatment with insulin 2. Cerobrovascular insult or other disease of the brain 3. Insufficiency of the heart or lungs 4. Liverdisease with ALAT \> 200 U/L 5. hemoglobin \< 7,0 mmol/l 6. Cancer 7. Alcohol abuse 8. Medical treatment with psycopharmaca or/and analgetics 9. Pregnancy and breast feeding, 10 blood donation one month before the study.

Design outcomes

Primary

Measure	Time frame
GFR, clearance of sodium and lithium, fractional excretion of sodium and lithium, U-AQP-2, total sodium excretion, albumin excretion rate and free water clearance.	6 months

Secondary

Measure	Time frame
AVP, Ang-II, Aldo, ANP, BNP, PRC, BP, HR.	6 months

Countries

Denmark

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026